Hair Loss Treatment Raw Ru-58841 Powder Ru-58841

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: XMHT-Ru-58841
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Ru-58841
• Name: Ru-58841 Powder
• Appearance: White to off-White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Hair Loss Treatment
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 154992-24-2
• Mf: C17h18f3n3o3
• MW: 369.344
• Density: 1.39
• Boiling Point: 493.6 C at 760 Mmhg
• Refractive Index: 1.559
• Transport Package: Negotiable
• Specification: 99%
• Trademark: XMHT
• Origin: Shaanxi
• Production Capacity: 3000kg/Month

Product Description

Hair Loss Treatment Raw Ru-58841 Powder Ru-58841

Product Description

Product Details

Product Name	Ru-58841
Appearance	White Powder
CAS	154992-24-2
MF	C17H18F3N3O3
MW	369.344

RU58841 is a potent and highly selective non-steroidal antiandrogen, distinguished by its design for topical administration and local action. Its primary mechanism involves high-affinity competitive antagonism of the androgen receptor (AR) within cutaneous tissues, such as hair follicles and sebaceous glands. Unlike systemic antiandrogens, RU58841 is engineered to minimize transdermal absorption, thereby confining its pharmacological activity to the application site and reducing the risk of systemic hormonal side effects. This localized action makes it an exceptionally valuable tool in dermatological, endocrine, and pharmacological research for dissecting the specific roles of androgen signaling in skin biology and for exploring targeted therapeutic strategies for androgen-dependent disorders.

Application&Function

The foremost research application of RU58841 lies in the study of androgenetic alopecia (AGA) pathophysiology and treatment. Its utility is rooted in its ability to directly block the binding of (DHT)—the primary mediator of hair follicle miniaturization—to the AR present in dermal papilla cells and other follicular components. By inhibiting this interaction, RU58841 prevents the downstream genomic and non-genomic signaling cascades that lead to the progressive shortening of the anagen (growth) phase, follicular miniaturization, and eventual hair thinning. Preclinical studies using animal models have demonstrated that topical RU58841 can effectively prevent androgen-driven hair loss and, in some cases, stimulate hair regrowth by potentially reversing miniaturization and prolonging anagen. Research employing RU58841 is crucial for elucidating the precise spatial and temporal dynamics of AR signaling within the hair follicle niche, understanding the roles of AR co-regulators, and evaluating the efficacy of local antiandrogen therapies without the confounding effects of systemic hormonal modulation.

Beyond hair follicle biology, RU58841 serves as a critical investigative tool for other androgen-mediated dermatological conditions. A significant area of focus is acne vulgaris research, where androgens contribute to sebaceous gland hyperplasia and increased sebum production. By topically antagonizing AR in sebocytes and periglandular tissue, RU58841 enables researchers to isolate and study the direct effects of local androgen blockade on sebum secretion rates, lipid composition, and comedogenesis. This helps delineate the specific contributions of hormonal signaling from other acne pathogenic factors like Cutibacterium acnes colonization and inflammation. Similarly, RU58841 is used in hirsutism research as a model to assess the potential for localized reduction of unwanted facial or body hair through direct follicular AR inhibition.

Specification